Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + etoposide + prednisolone
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of four drugs: cyclophosphamide, epirubicin, etoposide, and prednisolone. Cyclophosphamide is an alkylating agent that interferes with DNA replication; epirubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II; etoposide is a topoisomerase II inhibitor causing DNA strand breaks; and prednisolone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. This regimen has been studied primarily in the treatment of small cell lung cancer (SCLC) and certain lymphomas, showing high response rates but also notable toxicities such as myelosuppression, alopecia, nausea, and vomiting[1][3]. The combination may be considered as an alternative to standard regimens in SCLC or used in elderly patients with lymphoma.
- Other names
- CEEP
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + etoposide + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + etoposide + prednisolone.